CRISM Therapeutics Corporation
AMMCF
$6.77
$6.573,309.57%
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | -220.18% | -301.57% | -427.27% | -675.51% | -1,376.69% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1,469.92% | 7,296.53% | 1,072.97% | 835.36% | 60.66% |
| Change in Net Operating Assets | -- | -- | -- | -- | -- |
| Cash from Operations | 21.19% | -48.99% | -193.86% | -212.41% | -237.98% |
| Capital Expenditure | -- | -- | 100.00% | 56.69% | 23.60% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 6,107.05% | -- | -- | -763.50% | -278.37% |
| Cash from Investing | 6,935.81% | 13,437.62% | 10,441.28% | 7,863.40% | -400.98% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -100.00% | -100.00% | 0.00% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -3,348.66% | -8,722.32% | -8,410.14% | -8,129.57% | -- |
| Foreign Exchange rate Adjustments | 642.11% | 452.63% | 31.58% | -70.76% | -90.40% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 106.12% | 128.28% | 170.15% | 9.87% | -223.94% |
